Abstract
Objective: Review nonclinical and clinical trial data for hepatic effects of duloxetine. Methods: Review studies of toxicology, metabolism, mitochondrial effects, and clinical trials. Results: Nonclinical studies revealed no treatment-related transaminase elevations and no effects of duloxetine on mitochondrial beta-oxidation in rat hepatocytes. In patients with a normal baseline alanine transaminase (ALT), duloxetine was associated with elevated transaminases > 3X ULN in about 1% of patients. ALT and aspartate transaminase values peaked at 8 weeks, alkaline phosphatase steadily increased to maximum value at Week 52 and mean total bilirubin values were not increased. Hepatic-related treatment-emergent adverse events were uncommon. Seven of 23,000 duloxetine- and 2/6000 placebo-treated patients met criteria for modified Hys rule (significant elevation of both ALT and total bilirubin) but were complicated by contributing factors such as excessive alcohol consumption (n=3), gall stones, common bile duct calculus, hepatitis C, and liver adenocarcinoma (n=1 each). Conclusions: Duloxetine has an effect on the liver, manifested by transient, self-limiting transaminase elevations. Rare events characterized as hepatocellular injury, cholestatic injury, or mixed type of hepatic injury have been reported. The pattern of liver effects was different from that in laboratory animals.
Keywords: Duloxetine, hepatic, clinical, nonclinical
Current Drug Safety
Title: Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Volume: 3 Issue: 2
Author(s): Joachim Wernicke, Beth Pangallo, Fujun Wang, Isabelle Murray, Judith W. Henck, Mary Pat Knadler, Deborah N. D'Souza and Jack P. Uetrecht
Affiliation:
Keywords: Duloxetine, hepatic, clinical, nonclinical
Abstract: Objective: Review nonclinical and clinical trial data for hepatic effects of duloxetine. Methods: Review studies of toxicology, metabolism, mitochondrial effects, and clinical trials. Results: Nonclinical studies revealed no treatment-related transaminase elevations and no effects of duloxetine on mitochondrial beta-oxidation in rat hepatocytes. In patients with a normal baseline alanine transaminase (ALT), duloxetine was associated with elevated transaminases > 3X ULN in about 1% of patients. ALT and aspartate transaminase values peaked at 8 weeks, alkaline phosphatase steadily increased to maximum value at Week 52 and mean total bilirubin values were not increased. Hepatic-related treatment-emergent adverse events were uncommon. Seven of 23,000 duloxetine- and 2/6000 placebo-treated patients met criteria for modified Hys rule (significant elevation of both ALT and total bilirubin) but were complicated by contributing factors such as excessive alcohol consumption (n=3), gall stones, common bile duct calculus, hepatitis C, and liver adenocarcinoma (n=1 each). Conclusions: Duloxetine has an effect on the liver, manifested by transient, self-limiting transaminase elevations. Rare events characterized as hepatocellular injury, cholestatic injury, or mixed type of hepatic injury have been reported. The pattern of liver effects was different from that in laboratory animals.
Export Options
About this article
Cite this article as:
Wernicke Joachim, Pangallo Beth, Wang Fujun, Murray Isabelle, Henck W. Judith, Knadler Pat Mary, D'Souza N. Deborah and Uetrecht P. Jack, Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data, Current Drug Safety 2008; 3 (2) . https://dx.doi.org/10.2174/157488608784529189
DOI https://dx.doi.org/10.2174/157488608784529189 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design Inhibition of Monoamine Neurotransmitter Transporters andCentral Nervous System Stimulation Induced by Synthetic Local Anesthetics and Cocaine: A Comparative Review
Current Medicinal Chemistry - Central Nervous System Agents MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Efficient High-throughput Techniques for the Analysis of Disease- Resistant Plant Varieties and Detection of Food Adulteration
Current Protein & Peptide Science Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain
Current Pharmaceutical Design Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Current Pharmaceutical Biotechnology TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Structural Chromosome Abnormalities Associated with Obesity: Report of Four New Subjects and Review of Literature
Current Genomics A Retrospective, Multi-Center Cohort Study Evaluating the Severity- Related Effects of Cerebrolysin Treatment on Clinical Outcomes in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Low-Dose Mercury Exposure in Early Life: Relevance of Thimerosal to Fetuses, Newborns and Infants
Current Medicinal Chemistry Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Neurobiological Mechanisms of Stress Resilience and Implications for the Aged Population
Current Neuropharmacology Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
CNS & Neurological Disorders - Drug Targets Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Purinergic Signalling and Neurological Diseases: An Update
CNS & Neurological Disorders - Drug Targets